Phase 1
Kindness. Respect. Innovation. Only one of those words typically features in biotech mission statements, but at Ikena Oncology, all three are important – and have been from day one.
The first week of November was marked by numerous clinical trial announcements. Here’s a look.
Sangamo Therapeutics announced positive preliminary findings from its ongoing Phase I/II STAAR clinical trial in Fabry disease.
While some may wonder about the commercial future of these late-to-the-market solutions, the developers themselves are taking a long view.
This week, the U.S. Food and Drug Administration accepted Investigational New Drug Applications for multiple companies, clearing the way for clinical development.
The drug makers have until February 28, 2022 to review their findings and analytical processes for the drug they are developing to treat relapsed and/or refractory multiple myeloma.
Centessa showed positive early results from its Phase I Part B study on a potential drug that could direct mutation activity in patients with a particular gene that can cause liver and lung diseases.
As the world marks a grim milestone of 5 million COVID-19 deaths, public health officials are keeping a close watch on a substrain of the Delta variant.
Daiichi Sankyo announced the decision in its third quarter financial report this morning, where it said that the Phase I data yielded no clear responses in GIST patients.
Yet another busy week for clinical trial news. Here’s a look.
PRESS RELEASES